BEIJING, June 24 /PRNewswire-Asia/ -- Cellonis, a Beijing and HK-based biotech company, with its new personalized diabetes treatment concept has demonstrated an amazing improvement in their treated patients' conditions. The ongoing clinical study shows the treatment's best case could reconstruct a patient's natural insulin production and even reverse later complications like kidney failure. Treated patients may have the chance to return to the normal activities non-diabetes sufferers take for granted.

New technology developed by University of Virginia inventors involving adipose stem cells - adult stem cells found in fatty tissue - could one day be used to treat patients with severe wounds and other serious conditions.

The U.Va. Patent Foundation recently licensed a series of novel ways to identify, grow and use these cells to the GID Group, putting the U.Va. discoveries on the path to commercialization.

Over the past few years, researchers have determined that adipose stem cells have therapeutic potential in a variety of areas, including tissue engineering and treatment of chronic wounds, like those caused by diabetic ulcers; diseases characterized by poor blood flow, such as cardiac ischemia, which leads to heart attacks; and severe burns.

Even as regulatory agencies express abundant caution, adult stem cell therapies are moving steadily toward the clinic and through development for multiple applications. Investors have become more sophisticated about distinguishing between adult stem cell therapies and embryonic stem cell therapies as well as the potential risks, complications, and costs involved in each.

Osiris is a contender to be the first to obtain positive Phase III results for an adult stem cell product. In May the company restarted patient enrollment into a late-stage trial evaluating Prochymal in patients with treatment-resistant Crohn disease; the trial was stopped in March 2009 due to concerns that there was a flaw in the trial design. In February, though, Osiris reported that it showed potential when used as a rescue therapy in children suffering from severe treatment-resistant graft vs. host disease (GvHD). The product is also in Phase II trials in heart attack, type 1 diabetes, and COPD patients.

Athens, Ga. - Two University of Georgia animal science researchers introduced to the world 13 pigs that may hold the key to new therapies to treat human diseases, including diabetes. Announced this week, the discovery marks the first time pluripotent stem cells, or cells that can turn into any type of cell in the body, have been created from adult livestock.

COLUMBIA, Md. - May 4, 2010 - Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.